Sophiris Bio (SPHS) Says Topsalysin Data from Phase 2a Localized Prostate Cancer Study to be Presented at EAU
Tweet Send to a Friend
Sophiris Bio Inc. (NASDAQ: SPHS) today announced that data from its successful Phase 2a study of topsalysin, which evaluated the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
